Dr. Anna Moore has recently joined Michigan State University (MSU) the Professor of Radiology and Physiology at the Department of Radiology, College of Human Medicine. She is the Director of Precision Health Program and the Assistant Dean at the College of Human Medicine. Prior to joining MSU, she was a Professor of Radiology at Massachusetts General Hospital (MGH)/Harvard Medical School. Dr. Moore received her M.S. degree in Chemistry from Moscow State University (Russia) and obtained her Ph.D. degree in Bioorganic Chemistry from the Institute of Biochemistry, Russian Academy of Sciences. Her research is aimed at developing molecular imaging theranostic agents for cancer imaging and therapy. She is a co-founder of TransCode Therapeutics, a company that is aimed at bringing these therapies into clinic. Dr. Moore is a recipient of multiple grant awards from the NIH and other funding agencies and published her work in the most prestigious journals including Nature, Nature Medicine, Nature Biotechnology, PNAS and others. Dr. Moore has served as a Member of the Affiliated Faculty of Harvard-MIT Division of Health Sciences and Technology. For her contribution to teaching courses at international meetings she was awarded with the “Outstanding Teacher Award” from the International Society for Magnetic Resonance in Medicine (ISMRM). She was elected twice as a Chair of the Cellular and Molecular Imaging study group at this society. She was awarded a Distinguished Investigator Award from the Academy of Radiology Research in 2014. She served two terms as a Member of the Board of Trustees and the past Treasurer of the World Molecular Imaging Society (WMIS). For her service to the Society Dr. Moore was elected as a Fellow of the World Molecular Imaging Society.
Emerging Therapeutics Showcase:
Michigan State University
By redefining health and disease we can drive medicine toward health and away from treating symptoms. In this way, we refocus medicine on the restoration of health rather than amelioration of symptoms.
Image-Guided Therapy For Metastatic Breast Cancer
This talk will cover a new therapy for treating metastatic breast cancer based on silencing microRNA-10b responsible for viability of meta-static cells. Pre-clinical studies showed elimination of established metastasis in mice using image-guided nanoparticles conjugated to anti-miR-10b antisense oligonucleotides. Studies in large animals are under way; human clinical trials are to follow.
The PMWC 2020 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.